ONLY BENLYSTA IS DESIGNED TO TARGET BLyS,

AN UNDERLYING CAUSE OF LUPUS AND LUPUS NEPHRITIS1,2

ONLY BENLYSTA IS
DESIGNED TO TARGET
BLyS, AN UNDERLYING CAUSE OF LUPUS AND LUPUS NEPHRITIS1,2

 

 

Image: Mechanism of action for BENLYSTA

The clinical relevance of these results has not been definitively established.

* BENLYSTA does not directly bind to B cells or
directly deplete B-cell population.3,4

BLyS IS ELEVATED IN PATIENTS WITH LUPUS5

BLyS IS ELEVATED IN
PATIENTS WITH LUPUS5

Icon: BLyS levels

BLyS levels correlate with lupus disease activity and anti-dsDNA titers in many patients1

 

BLyS levels correlate with lupus disease activity and anti-dsDNA titers in many patients1

41% reduction icon

Adult patients with lupus on BENLYSTA experienced a 41% reduction in anti-dsDNA levels over 52 weeks5

Adult patients with lupus
on BENLYSTA experienced a 41% reduction
in anti-dsDNA levels
over 52 weeks5

The clinical relevance of these results has not been definitively established.

The clinical relevance of these results has not
been definitively established.

Anti-dsDNA = anti-double-stranded DNA;
BLyS = B-lymphocyte stimulator protein.

REDUCTION IN KEY SEROLOGICAL MARKERS
WAS SEEN AS EARLY
AS WEEK 8

At Week 52, adult patients with lupus on BENLYSTA showed:

At Week 52, adult patients with
lupus on BENLYSTA showed:

Icon: Down arrow

Reductions in:

  • IgG
  • Anti-dsDNA antibodies*
  • IgG
  • Anti-dsDNA antibodies*
  •  

Icon: Up arrow

Increases in:

  • Complement (C3 and C4)†

SEE THE DATA

SEE THE DATA

The clinical relevance of these results has not
been definitively established.

* In patients who were positive for
anti-dsDNA ≥30 IU/mL.

† In patients with low complement levels at baseline.

Anti-dsDNA = anti-double-stranded DNA;
IgG = Immunoglobulin G.

REDUCTIONS IN B-CELL POPULATIONS5

Icon: Target BLyS

At Week 52, adult patients with lupus on BENLYSTA showed:

Significant reductions in:

  • CD19+ B cells
  • CD20+ B cells
  • Naïve and activated B cells
  • Lupus B-cell subset

The clinical relevance of these results has not been definitively established.

BENLYSTA REDUCES
AUTOANTIBODIES AND
NORMALIZES LOW COMPLEMENT LEVELS5

Median change in
biomarkers over time

Pooled data from BLISS-52 and
BLISS-76

Median change in biomarkers over time charts
Median change in biomarkers over time charts

The clinical relevance of these results has not been definitively established.

 

The clinical relevance of these results has
not been definitively established.

Used with permission from Stohl W, et al.
Arthritis Rheum.
2012;64:2328-2337 ©2012
John Wiley and Sons.

* In patients who were positive for
anti-dsDNA ≥30 IU/mL.

† In patients with low complement levels
at baseline.

Anti-dsDNA = anti-double-stranded DNA;
ST = standard therapy.

Start BENLYSTA now to target underlying disease

Patient with hand on hip
Patient with hand on hip